The Exocrine Pancreatic Insufficiency industry trends have evolved rapidly over the past 18 months, driven by innovation and strategic collaborations. Key developments include Takeda’s acquisition of a biotech firm specializing in enzyme delivery technologies, enhancing its portfolio with a novel delayed-release capsule formulation. Partnerships have surged, with Viatris and a leading CRO co-developing patient-centric dosing solutions to improve adherence. Regulatory momentum is evident, as the FDA recently updated guidelines to prioritize patient-reported outcomes in clinical trials, aligning with a growing emphasis on real-world evidence. Meanwhile, digital health integration has gained traction, with startups like GastroPharma launching AI-powered apps to monitor symptom patterns and medication efficacy. Funding activity remains robust, with Series B rounds totaling $50M+ fueling advancements in precision dosing and orphan drug pipelines. The market is also witnessing a shift toward decentralized trials and expanded access programs, reflecting heightened focus on patient-centric care. As therapies become more tailored and accessible, the EPI landscape is poised for transformative growth in 2024–2025.
